The Boston Globe

Business

Boston.com

AVEO set to move from start-up to producer

Launch of kidney cancer drug will be important step for Cambridge firm

By Carolyn Y. Johnson

 |  Globe Staff  

  April 16, 2012

A decade after AVEO Pharmaceuticals was founded, based on the idea that it would be possible to create better cancer drugs if researchers simply started with more accurate models of human cancer, the company is on the cusp of a major growth spurt. This year, AVEO plans to apply for federal approval of its first drug, for kidney cancer, and it is in the midst of a year-long hiring spree, with plans to add 120 new employees.

Stay with the story. Get full access to BostonGlobe.com for just 99¢

Unlimited access to BostonGlobe.com for only 99¢ for the first 4 weeks. You can cancel at any time.

  • The FULL story all day: Enjoy all of the high-quality, in-depth journalism in the print edition of the Boston Globe — plus breaking news that's updated 24/7.
  • A truly reader-friendly format: It's online news that looks and reads just like the newspaper — uncluttered, uninterrupted.
  • Breakthrough technology: The responsive design automatically adapts content so it always reads perfectly on the digital device of your choice.
Get started today

Free access for home delivery subscribers.

Just need to link your home delivery account; one easy step.

Link my home delivery account

BostonGlobe.comSubscriber Log In

Contact us for help